Skip to main content

Advertisement

SpringerLink
Log in

Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients

  • Fungal Infections in Transplantation (S Shoham, Section Editor)
  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The aim of this paper is to discuss clinical interactions between the azole antifungals and the commonly used immunosuppressants for the prevention of rejection in solid organ transplant recipients.

Recent Findings

Drug–drug interactions between azole antifungals and immunosuppressants have largely been reported in healthy subjects or the hematopoietic stem cell transplant (HSCT) population. Data is emerging evaluating these interactions in solid organ transplant recipients.

Summary

Drug–drug interactions between azole antifungals and immunosuppressants occur at or near the same magnitude as in healthy subjects or the HSCT population. Factors affecting these drug–drug interactions include the influence of the interacting agents on CYP enzymes, the doses of the drugs administered, and the route of administration of both the azoles and immunosuppressants. Care and caution should be exercised when managing solid organ transplant patients receiving medications from both classes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Shoham S, Marr K. Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 2012;7(5):639–55. https://doi.org/10.2217/fmb.12.28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38–54.

    Article  CAS  PubMed  Google Scholar 

  3. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.

    Article  CAS  PubMed  Google Scholar 

  4. Nivoix Y, Leveque D, Herbrecht R, Koffel J, Beretz L, et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet. 2008;47:779–92.

    Article  CAS  PubMed  Google Scholar 

  5. Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19:e12751.

    Article  Google Scholar 

  6. • Sparkes T, Lemonovich TL, on behalf of the AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants – Guidelines from the American Society of Transplantation Infectious Diseases Community Practice. Clin Transplant. 2019;33:e13510 The American Society of Transplantation’s Infectious Diseases subgroup published clinical guidelines for the management of drug–drug interactions between anti-infective agents, including antifungals, and immunosuppressants.

    PubMed  Google Scholar 

  7. Leopoldo M, Nardulli P, Contino M, Leonetti F, Luurtsema G, et al. An updated review on P-glycoprotein inhibitors. Expert Opin Ther Patents. 2019;29:455–61.

    Article  CAS  Google Scholar 

  8. • Bellman R, Smuskiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737–79 Excellent review on the clinical relevance of the pharmacokinetics of the azole antifungals used clinically for the treatment and prevention of invasive fungal infections.

    Article  Google Scholar 

  9. Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. ID Clin N Am. 2016;30:51–83.

    Google Scholar 

  10. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427–30.

    Article  CAS  PubMed  Google Scholar 

  11. • He J, Yu Y, Yin C, Liu H, Zou H, et al. Clinically significant drug-drug interaction between tacrolimus and fluconazole in stable renal transplant recipient and literature review. J Clin Pharm Therapeutics. 2020;45:264–9 Clinical data describing the concurrent use of fluconazole and tacrolimus for the management of candida esophagitis in a renal transplant recipient.

    Article  Google Scholar 

  12. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation. 2002;10:1477–8.

    Article  Google Scholar 

  13. Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother. 2008;42:1711–6.

    Article  CAS  PubMed  Google Scholar 

  14. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs. 2007;67:269–98.

    Article  CAS  PubMed  Google Scholar 

  15. Romero AJ, Le PP, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther. 2002;2001(71):226–34.

    Article  Google Scholar 

  16. Spriet I, Grootaert V, Meyfroidt G, Debaveye Y, Willems L. Switching from intravenous to oral tacrolimus and voriconazole leads to more pronounced drug-drug interaction. Eur J Clin Pharmacol. 2013;69:737–8.

    Article  PubMed  Google Scholar 

  17. Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ transplant recipients. Am J Transplant. 2017;17:2372–80.

    Article  CAS  PubMed  Google Scholar 

  18. Ceberio I, Dai K, Devlin SM, Barke JN, Castrol-Malaspina H, et al. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015;50:438–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. • Huppertz A, Ott C, Bruckner T, Foerster KI, Burhenne J, et al. Prolonged-release tacrolimus is less susceptible to interaction with strong CYP3A4 inhibitor voriconazole in healthy volunteers. Clin Pharm Ther. 2019;106:1290–8 Data assessing the extent of a drug–drug interaction between prolonged-release tacrolimus and voriconazole in healthy subjects.

    Article  CAS  Google Scholar 

  20. VFend®(Voriconazole) [package insert]. Pfizer. New York, NY. May 2011.

  21. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825–34.

    Article  CAS  PubMed  Google Scholar 

  22. Deyo JC, Nicolsen N, Lachiewicz A, Koslowski T. Salvage treatment of mucormycosis post-liver transplant with posaconazole during sirolimus maintenance therapy. J Pharm Practice. 2017;30:261–5.

    Article  Google Scholar 

  23. Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;76:1647–57.

    Article  CAS  PubMed  Google Scholar 

  24. Groll AH, Desai A, Han D, Howieson C, Kato K, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2016;6:76–85.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Rivosecchi RM, Clancy CJ, Shields RK, Ensor CR, Shullo MA, et al. Effects of isavuconazole on the plasma concentrations of tacrolimus among solid organ transplant patients. Antimicrobial Agents Chemother. 2017;61:e00970–17.

    Article  CAS  Google Scholar 

  26. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation. 1991;52(6):1086–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vasquez EM, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transpl. 2001;15:95–9.

    Article  CAS  Google Scholar 

  28. Pfizer Wyeth Pharmaceuticals LLC. Rapamune (sirolimus) United States prescribing information. PA: Philadelphia; January 2020.

  29. Novartis Pharmaceuticals Corporation. Zortress (everolimus) United States prescribing information. NJ: East Hanover; January 2018.

  30. El-Groudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine A in kidney transplant recipients: ten-year follow-up. Transplantation. 2004;77(9):1371–6.

    Article  Google Scholar 

  31. El-Dahshan KF, Bakr MA, Donia AF, Badr AE, Sobh MA. Ketoconazole-tacrolimus coadministration in kidney transplant recipients; two-year results of a prospective randomized study. Am J Nephrol. 2006;26:293–8.

    Article  CAS  PubMed  Google Scholar 

  32. Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation. 2003;77(3):474–5.

    Article  Google Scholar 

  33. Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, et al. Everolimus versus azathioprine in a cyclosporine and ketoconazole based immunosuppressive therapy in kidney transplant:3-year follow-up of an open-label, prospective, cohort, comparative clinical trial. Transplant Proc. 2010;42:270–2.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Antimicrobial Stewardship, Department of Pharmacy, The Johns Hopkins Hospital, 600 North Wolfe Street, Halsted 837, Baltimore, MD, 21287, USA

    Kathryn Dzintars

  2. Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA

    Lindsey P. Toman

Authors
  1. Kathryn Dzintars
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lindsey P. Toman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathryn Dzintars.

Ethics declarations

Conflict of Interest

Kathryn Dzintars and Lindsey Toman declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Fungal Infections in Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dzintars, K., Toman, L.P. Interpretation and Understanding of Clinical Drug Interactions Between Azoles and Immunosuppressants in Solid Organ Transplant Recipients. Curr Fungal Infect Rep 14, 391–396 (2020). https://doi.org/10.1007/s12281-020-00404-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-020-00404-4

Keywords

Search

Navigation